Erasca, Inc.

NasdaqGS:ERAS Rapport sur les actions

Capitalisation boursière : US$768.1m

Erasca Gestion

Gestion contrôle des critères 3/4

Erasca's CEO is Jonathan Lim, appointed in Jul 2018, has a tenure of 6.33 years. total yearly compensation is $5.41M, comprised of 11.5% salary and 88.5% bonuses, including company stock and options. directly owns 11.46% of the company’s shares, worth $88.01M. The average tenure of the management team and the board of directors is 3.5 years and 6.1 years respectively.

Informations clés

Jonathan Lim

Directeur général

US$5.4m

Rémunération totale

Pourcentage du salaire du PDG11.5%
Durée du mandat du directeur général6.3yrs
Propriété du PDG11.5%
Durée moyenne d'occupation des postes de direction3.5yrs
Durée moyenne du mandat des membres du conseil d'administration6.1yrs

Mises à jour récentes de la gestion

Recent updates

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Oct 15
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Erasca: New Focus After Restructuring, But Need More Differentiation

Sep 30

Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

Feb 21
Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

Nov 16
We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

Jun 28
Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Jan 20
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Erasca forms clinical trial partnership with Pfizer for cancer therapy

Oct 20

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Sep 23
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca adds 10% ahead of R&D Day

Sep 07

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Jul 18

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Apr 12
We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Dec 28
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Analyse de la rémunération des PDG

Comment la rémunération de Jonathan Lim a-t-elle évolué par rapport aux bénéfices de Erasca?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$158m

Mar 31 2024n/an/a

-US$127m

Dec 31 2023US$5mUS$623k

-US$125m

Sep 30 2023n/an/a

-US$231m

Jun 30 2023n/an/a

-US$236m

Mar 31 2023n/an/a

-US$240m

Dec 31 2022US$8mUS$593k

-US$243m

Sep 30 2022n/an/a

-US$138m

Jun 30 2022n/an/a

-US$149m

Mar 31 2022n/an/a

-US$141m

Dec 31 2021US$850kUS$498k

-US$123m

Sep 30 2021n/an/a

-US$154m

Jun 30 2021n/an/a

-US$119m

Mar 31 2021n/an/a

-US$96m

Dec 31 2020US$2mUS$300k

-US$102m

Rémunération vs marché: Jonathan's total compensation ($USD5.41M) is above average for companies of similar size in the US market ($USD3.24M).

Rémunération et revenus: Jonathan's compensation has been consistent with company performance over the past year.

PDG

Jonathan Lim (52 yo)

6.3yrs

Titularisation

US$5,407,446

Compensation

Dr. Jonathan E. Lim, M.D., Co-founded Erasca, Inc. in July 2018 and has been its Executive Chairman since October 2018 and Chief Executive Officer since March 2019. Dr. Lim has also served as a Venture Par...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Jonathan Lim
Co-Founder6.3yrsUS$5.41m11.46%
$ 88.0m
David Chacko
CFO & Chief Business Officer3.9yrsUS$2.43m0.087%
$ 671.1k
Ebun Garner
General Counsel & Corporate Secretary3.6yrsUS$2.02m0.0034%
$ 26.4k
Michael Varney
Chairman of Research & Development4.3yrsUS$199.05k0%
$ 0
Nik Chetwyn
Chief Operating Officer3.5yrspas de donnéespas de données
Lisa Tesvich-Bonora
Chief People Officer2.8yrspas de donnéespas de données
Brian Baker
Senior Vice President of Finance3.5yrspas de donnéespas de données
Chandra Lovejoy
Chief Regulatory Affairs Officer3.5yrspas de donnéespas de données
Robert Shoemaker
Senior Vice President of Research3yrspas de donnéespas de données
Shannon Morris
Chief Medical Officer2.5yrspas de donnéespas de données
Minli Xie
Senior Vice President of Pharmaceutical Development & Operations2yrspas de donnéespas de données
Dawei Xuan
Senior Vice President of Clinical Pharmacology1.5yrspas de donnéespas de données

3.5yrs

Durée moyenne de l'emploi

52.5yo

Âge moyen

Gestion expérimentée: ERAS's management team is considered experienced (3.5 years average tenure).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Jonathan Lim
Co-Founder6.1yrsUS$5.41m11.46%
$ 88.0m
Michael Varney
Chairman of Research & Development4.3yrsUS$199.05k0%
$ 0
George Demetri
Scientific Advisory Board Memberno datapas de donnéespas de données
Alexander Casdin
Independent Director6.3yrsUS$167.54k0.24%
$ 1.8m
Pratik Multani
Independent Director6.3yrsUS$156.54k0.061%
$ 470.2k
Kevan Shokat
Scientific Advisory Board Memberno datapas de donnéespas de données
James Bristol
Independent Director6.4yrsUS$180.08k0.073%
$ 564.4k
Julie Hambleton
Independent Director3.7yrsUS$165.04k0.0021%
$ 16.3k
Ryan Corcoran
Scientific Advisory Board Memberno datapas de donnéespas de données
Valerie Harding-Start
Independent Director5.4yrsUS$165.54k0.0078%
$ 59.8k
Karen Cichowski
Scientific Advisory Board Memberno datapas de donnéespas de données
Pablo Rodriguez-Viciana
Scientific Advisory Board Memberno datapas de donnéespas de données

6.1yrs

Durée moyenne de l'emploi

65yo

Âge moyen

Conseil d'administration expérimenté: ERAS's board of directors are considered experienced (6.1 years average tenure).